9 completed, 2 recruiting, 1 unknown, 1 withdrawn. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 9, Recruiting 2, Unknown 1, Withdrawn 1 |
Follow Iohexol: new trials by email Literature Review of Iohexol trials Research Report on Iohexol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluorescent Probe for Assessment of Renal Elimination Relmapirazin, Iohexol, Medibeacon tGFR monitor - Augmented Renal Clearance, Critical Illness | Phase 4 | Recruiting | Aaron Cook | 200 | 2026-09-01 | 2026-10-07 |
| Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) Iohexol - Bacterial Infection | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 161 | 2025-02-12 | 2026-07-31 |
| Chest CT Using Low-concentration Iodine Contrast Media Iohexol (320mgI/mL) with 120kVp, Iohexol (320mgI/mL) with 100kVp, Iohexol (270mgI/mL) with 100kVp - Pulmonary Disease | Phase 4 | Unknown | Jung Im Jung | 370 | 2023-11-24 | 2024-07-25 |
| CT TAVR Abdomen Study Iodinated Contrast Agent (Omnipaque), Dual Energy CT - Transcatheter Aortic Valve Replacement | Phase 4 | Recruiting | University of Maryland, Baltimore | 164 | 2023-09-19 | 2026-07-01 |
| Pediatric Risk of Hypothyroidism With Iodinated Contrast Media Iohexol, Iodixanol, Iopromide - Hypothyroidism | Phase 4 | Withdrawn | GE Healthcare | 2022-03-01 | 2022-04-20 | |
| Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Iodixanol, Iohexol - Coronary Artery Disease, Contrast Media Reaction | Phase 4 | Completed | Minneapolis Heart Institute Foundation | 62 | 2021-09-30 | 2026-08-19 |
| Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 LCZ 696, Placebo, Para-aminohippurate - Heart Failure | Phase 4 | Completed | Yale University | 46 | 2021-05-27 | 2026-10-27 |
| Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients IHX-CL measurements, Iohexol - Transgender, Renal Function | Phase 4 | Completed | University of California, San Diego | 42 | 2020-09-17 | 2022-03-03 |
| Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 LCZ 696, Icatibant, placebo - Heart Failure | Phase 4 | Completed | Vanderbilt University Medical Center | 46 | 2019-11-01 | 2026-08-11 |
| Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight Iohexol - Contrast Media Dosing | Phase 4 | Completed | Nova Scotia Health Authority | 239 | 2018-02-21 | 2019-01-31 |
| Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults STB, TVD, ATR - HIV-1 Infection | Phase 4 | Completed | Gilead Sciences | 72 | 2014-12-15 | 2018-01-03 |
| Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance iohexol - HIV | Phase 4 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 300 | 2011-02-01 | 2016-03-10 |
| Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT Omnipaque, Gastroview - Healthy | Phase 4 | Completed | University of Alabama at Birmingham | 300 | 2007-08-01 | 2017-04-18 |
Heart Failure (2) · Bacterial Infections (1) · Coronary Artery Disease (1) · Critical Illness (1) · Hypothyroidism (1) · Lung Diseases (1)
Aaron Cook (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · GE Healthcare (1) · Gilead Sciences (1) · Jung Im Jung (1) · Minneapolis Heart Institute Foundation (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nova Scotia Health Authority (1) · University of Alabama at Birmingham (1) · University of California, San Diego (1) · University of Maryland, Baltimore (1) · Vanderbilt University Medical Center (1) · Yale University (1)
United States (8) · France (2) · Belgium (1) · Canada (1) · Ireland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Aaron M Cook, PharmD (1) · Andreu Costa, Md FRCPC (1) · Emmanouil Brilakis, MD, PhD (1) · Juan-Carlos Aycinena, MD (1) · Jung Im Jung, MD, PhD (1) · Michelle McNamara, MD (1) · Nancy J. Brown, M.D. (1) · Nancy J. Brown, MD (1) · Nimish Patel, PharmD (1) · Paul F. Sherwin, MD, PhD (1) · Philippe Bourrinet, PharmD (1) · Zuzana Jirakova Trnkova, MD, PhD (1)
2014 (1), 5UM1AI104681-12 (1)